A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination With Pembrolizumab in Patients With Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 28 Jul 2017
At a glance
- Drugs Margetuximab (Primary) ; Pembrolizumab
- Indications Gastric cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors MacroGenics
- 03 May 2017 According to a MacroGenics media release, company expects to complete enrollment of this study in 2017.
- 04 Apr 2017 Planned number of patients changed from 52 to 72.
- 04 Apr 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Dec 2017.